Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN KLEIN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1184620866
CMS profile
144056
Location
NEWPORT BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$36,805.74

184 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN KLEIN

NPI 1184620866 · CMS profile ID 144056

Allopathic & Osteopathic Physicians / Internal Medicine

NEWPORT BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN KLEIN, NPI 1184620866, CMS profile ID 144056. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RYAN KLEIN, NPI 1184620866, CMS profile ID 144056. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RYAN KLEIN, NPI 1184620866, CMS profile ID 144056, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–184 of 184 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

184 matching records · $36,805.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 184 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–184 of 184.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Circassia Pharmaceuticals Inc $12.0402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660215999 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9402/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465879 CMS
SANOFI PASTEUR INC. $11.6702/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691642761 CMS
Astellas Pharma US Inc $22.6202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655640259 CMS
GlaxoSmithKline, LLC. $2,400.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670340765 CMS
GlaxoSmithKline, LLC. $800.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671470805 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9402/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465881 CMS
GlaxoSmithKline, LLC. $16.4702/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670952351 CMS
GlaxoSmithKline, LLC. $16.7002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670609005 CMS
AstraZeneca Pharmaceuticals LP $16.3802/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685702543 CMS
GlaxoSmithKline, LLC. $3,600.0001/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670925935 CMS
GlaxoSmithKline, LLC. $22.2401/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671412619 CMS
Allergan Inc. $11.1001/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670666335 CMS
Janssen Pharmaceuticals, Inc $14.1501/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658850205 CMS
Grifols USA, LLC $20.4501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692608831 CMS
Amgen Inc. $21.3801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662984663 CMS
Otsuka America Pharmaceutical, Inc. $20.9201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687417251 CMS
Novartis Pharmaceuticals Corporation $22.7801/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659693843 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,340.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700058379 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,845.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465849 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.0801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465883 CMS
GlaxoSmithKline, LLC. $3,600.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670346604 CMS
GlaxoSmithKline, LLC. $3,600.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671188653 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.2701/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465885 CMS
GlaxoSmithKline, LLC. $13.4301/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671187923 CMS
AstraZeneca Pharmaceuticals LP $81.1901/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685907361 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,845.0001/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465851 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.1901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465887 CMS
GlaxoSmithKline, LLC. $5.6701/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670340771 CMS
GlaxoSmithKline, LLC. $7.9901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670737421 CMS
GlaxoSmithKline, LLC. $20.0001/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670740649 CMS
GlaxoSmithKline, LLC. $19.1401/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671166089 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,845.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465847 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $6.5401/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700465853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $36,805.74 184
PY2020 $3,309.26 142
PY2021 $10,030.65 205
PY2022 $8,344.84 182
PY2023 $12,622.12 222
PY2024 $3,732.13 163
PY2025 $3,553.97 153

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,561,622.39 318
PY2024 Principal investigator $961,837.56 314
PY2023 Principal investigator $617,104.05 80
PY2022 Principal investigator $616,975.34 88
PY2021 Principal investigator $392,976.03 62
PY2020 Principal investigator $296,194.85 43
PY2019 Principal investigator $480,642.80 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

318 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $144.41 12/31/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552215
Principal investigator 1 United Therapeutics Corporation $1,641.60 12/24/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386855
Principal investigator 1 United Therapeutics Corporation $1,641.60 12/24/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386875
Principal investigator 1 SANOFI US SERVICES INC. $8,546.00 12/22/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226139131
Principal investigator 1 Incyte Corporation $1,500.00 12/19/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560817
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 12/17/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772549
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772551
Principal investigator 1 Boehringer Ingelheim International GmbH $2.32 12/17/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772553
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 12/17/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772555
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 12/17/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772557
Principal investigator 1 GENZYME CORPORATION $396.00 12/15/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226139128
Principal investigator 1 PFIZER INC. $13,500.00 12/11/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228816697
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,891.50 12/09/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220791771
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,700.00 12/04/2025 Non-covered Recipient Entity
Newport Native Md
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235995333
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,632.97 12/03/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185552251
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 12/03/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772583
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/03/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772585
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/03/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772587
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623464
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623466
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623468
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772527
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772529
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772531
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772577
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772579
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 12/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772581
Principal investigator 1 United Therapeutics Corporation $380.70 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386887
Principal investigator 1 United Therapeutics Corporation $2,242.00 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386889
Principal investigator 1 United Therapeutics Corporation $3,005.10 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386893
Principal investigator 1 United Therapeutics Corporation $3,341.25 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386895
Principal investigator 1 United Therapeutics Corporation $11,848.95 12/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386903
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/26/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772571
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/26/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772573
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/26/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772575
Principal investigator 1 United Therapeutics Corporation $1,468.80 11/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386853
Principal investigator 1 United Therapeutics Corporation $1,134.00 11/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386869
Principal investigator 1 United Therapeutics Corporation $1,468.80 11/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386873
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/25/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772505
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/25/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772507
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/25/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772509
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/25/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772511
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/25/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772513
Principal investigator 1 SANOFI US SERVICES INC. $19,812.00 11/24/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226139123
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/20/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772495
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/20/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772497
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/20/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772499
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/20/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772501
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/20/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772503
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772543
Principal investigator 1 Boehringer Ingelheim International GmbH $4.64 11/19/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772545
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 11/19/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772547
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,178.20 11/14/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185552255
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,273.20 11/12/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791765
Principal investigator 1 United Therapeutics Corporation $4,838.40 11/12/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386863
Principal investigator 1 United Therapeutics Corporation $4,838.40 11/12/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386885
Principal investigator 1 United Therapeutics Corporation $7,932.60 11/12/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386897
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/07/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772485
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/07/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772487
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/07/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772489
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/07/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772491
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/07/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772493
Principal investigator 1 GlaxoSmithKline, LLC. $1,393.97 11/06/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192173968
Principal investigator 1 GlaxoSmithKline, LLC. $13,032.90 11/05/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192178780
Principal investigator 1 Incyte Corporation $290.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560776
Principal investigator 1 Incyte Corporation $793.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560782
Principal investigator 1 Incyte Corporation $375.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560786
Principal investigator 1 Incyte Corporation $1,240.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560794
Principal investigator 1 Incyte Corporation $4,720.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560801
Principal investigator 1 Incyte Corporation $430.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560807
Principal investigator 1 Incyte Corporation $380.00 11/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560812
Principal investigator 1 Insmed, Inc. $1,352.25 11/03/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646004
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 11/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623458
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 11/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623460
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 11/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623462
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772521
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772523
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772525
Principal investigator 1 AstraZeneca UK Limited $15,313.94 10/27/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185552225
Principal investigator 1 Boehringer Ingelheim International GmbH $373.12 10/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772533
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 10/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772535
Principal investigator 1 Boehringer Ingelheim International GmbH $18.56 10/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772537
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 10/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772539
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 10/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772541
Principal investigator 1 GlaxoSmithKline, LLC. $2,753.32 10/23/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192174941
Principal investigator 1 Insmed, Inc. $7,206.17 10/22/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646006
Principal investigator 1 GENZYME CORPORATION $7,825.00 10/20/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226139114
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,677.00 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185552241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.11 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,459.05 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.11 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,459.05 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,502.08 10/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251279
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,800.17 10/15/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185552233
Principal investigator 1 Genentech, Inc. $15,861.00 10/15/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211629002
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,304.50 10/14/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791763
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,801.14 10/10/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 No dispute reported 06/30/2026 1185552245
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,908.35 10/10/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185552257
Principal investigator 1 GlaxoSmithKline, LLC. $4,746.00 10/08/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192178757
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 10/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623452
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 10/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623454
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 10/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623456
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772515
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772517
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772519
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 09/24/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772467
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 09/24/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772469
Principal investigator 1 Boehringer Ingelheim International GmbH $32.48 09/24/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772471
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 09/24/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772473
Principal investigator 1 GlaxoSmithKline, LLC. $3,664.68 09/24/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192177708
Principal investigator 1 SANOFI US SERVICES INC. $18,000.00 09/22/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226139098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,916.38 09/19/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184240886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.00 09/19/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184240888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,067.27 09/19/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184240890
Principal investigator 1 GlaxoSmithKline, LLC. $51,730.99 09/18/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192174933
Principal investigator 1 United Therapeutics Corporation $29,146.50 09/10/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386865
Principal investigator 1 United Therapeutics Corporation $2,106.00 09/10/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386879
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772559
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772561
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772563
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772565
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772567
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772569
Principal investigator 1 Boehringer Ingelheim International GmbH $2.09 09/04/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772475
Principal investigator 1 Boehringer Ingelheim International GmbH $28.79 09/04/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772477
Principal investigator 1 Boehringer Ingelheim International GmbH $34.17 09/04/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772479
Principal investigator 1 Boehringer Ingelheim International GmbH $2.62 09/04/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772481
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 09/04/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772483
Principal investigator 1 Genentech, Inc. $10,296.00 09/03/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211628994
Principal investigator 1 Insmed, Inc. $5,535.75 09/02/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646000
Principal investigator 1 Insmed, Inc. $400.00 09/02/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646002
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 09/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623434
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 09/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623448
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 09/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623450
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772459
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772461
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772463
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,067.27 08/22/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,916.38 08/22/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184229963
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,500.00 08/21/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220791769
Principal investigator 1 GlaxoSmithKline, LLC. $10,575.72 08/20/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192177688
Principal investigator 1 GlaxoSmithKline, LLC. $2,961.68 08/20/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192177704
Principal investigator 1 United Therapeutics Corporation $13,697.10 08/06/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386905
Principal investigator 1 GENZYME CORPORATION $1,923.00 08/04/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226139063
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 08/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623438
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 08/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623444
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 08/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623446
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772453
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772455
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772457
Principal investigator 1 Genentech, Inc. $1,729.00 08/01/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211628997
Principal investigator 1 GlaxoSmithKline, LLC. $2,903.00 08/01/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192174952
Principal investigator 1 GlaxoSmithKline, LLC. $1,302.00 08/01/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177680
Principal investigator 1 GlaxoSmithKline, LLC. $156.00 08/01/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192178761
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,445.12 07/23/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185552237
Principal investigator 1 AstraZeneca UK Limited $18,500.00 07/18/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185552227
Principal investigator 1 GlaxoSmithKline, LLC. $93.55 07/16/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192174949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100,879.26 07/14/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (AirleafTM) No dispute reported 06/30/2026 1220791767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.00 07/14/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214868
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,968.10 07/11/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE) No dispute reported 06/30/2026 1185552249
Principal investigator 1 United Therapeutics Corporation $3,110.40 07/08/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386861
Principal investigator 1 United Therapeutics Corporation $3,110.40 07/08/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386883
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 07/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623436
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 07/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623440
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 07/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623442
Principal investigator 1 Boehringer Ingelheim International GmbH $223.56 07/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772445
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772447
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772449
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.00 06/27/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.00 06/27/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD MD INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211727
Principal investigator 1 Insmed, Inc. $0.44 06/25/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645986
Principal investigator 1 Insmed, Inc. $6,888.84 06/25/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645992
Principal investigator 1 Insmed, Inc. $0.46 06/25/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645996
Principal investigator 1 Insmed, Inc. $0.46 06/25/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645998
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 06/24/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623430
Principal investigator 1 Incyte Corporation $1,607.40 06/18/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560714
Principal investigator 1 GlaxoSmithKline, LLC. $7,439.95 06/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192177699
Principal investigator 1 GENZYME CORPORATION $8,724.00 06/16/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226139015
Principal investigator 1 SANOFI US SERVICES INC. $66.76 06/16/2025 Non-covered Recipient Entity
Newportnativemd Inc
A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226139008
Principal investigator 1 Genentech, Inc. $15,050.00 06/13/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211628991
Principal investigator 1 United Therapeutics Corporation $2,592.00 06/11/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386859
Principal investigator 1 United Therapeutics Corporation $2,592.00 06/11/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $67.96 06/05/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791761
Principal investigator 1 Incyte Corporation $24.78 06/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560718
Principal investigator 1 Incyte Corporation $8.64 06/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560733
Principal investigator 1 Incyte Corporation $3.84 06/03/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560738
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 06/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623426
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 06/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623428
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 06/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623432
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772419
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772421
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772423
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772425
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772427
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772429
Principal investigator 1 AstraZeneca Pharmaceuticals LP $601.47 05/28/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 No dispute reported 06/30/2026 1185552223
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772433
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772435
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772437
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772439
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772441
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/27/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772443
Principal investigator 1 GENZYME CORPORATION $396.00 05/27/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138998
Principal investigator 1 GlaxoSmithKline, LLC. $1,376.66 05/22/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192174945
Principal investigator 1 GlaxoSmithKline, LLC. $12,780.00 05/16/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192178776
Principal investigator 1 AstraZeneca Pharmaceuticals LP $57,599.47 05/13/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185552231
Principal investigator 1 GENZYME CORPORATION $5,358.00 05/12/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138994
Principal investigator 1 United Therapeutics Corporation $205.20 05/07/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386847
Principal investigator 1 United Therapeutics Corporation $1,468.80 05/07/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386851
Principal investigator 1 GlaxoSmithKline, LLC. $1,220.40 05/05/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177692
Principal investigator 1 Incyte Corporation $1.96 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560692
Principal investigator 1 Incyte Corporation $251.42 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560697
Principal investigator 1 Incyte Corporation $7.63 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560701
Principal investigator 1 Incyte Corporation $57.81 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560708
Principal investigator 1 Incyte Corporation $11.45 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560744
Principal investigator 1 Incyte Corporation $7.63 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560755
Principal investigator 1 Incyte Corporation $7.63 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560761
Principal investigator 1 Incyte Corporation $7.63 05/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560771
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 05/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623420
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 05/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623422
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 05/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623424
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 05/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772413
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 05/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772415
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 05/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772417
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 05/01/2025 Non-covered Recipient Entity
Huntington Beach Internal Medicine Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220772431
Principal investigator 1 Insmed, Inc. $11,481.40 04/30/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645984
Principal investigator 1 Insmed, Inc. $0.66 04/30/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645988
Principal investigator 1 Insmed, Inc. $1.38 04/30/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645990
Principal investigator 1 Insmed, Inc. $0.92 04/30/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645994
Principal investigator 1 United Therapeutics Corporation $1,468.80 04/23/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386871
Principal investigator 1 GlaxoSmithKline, LLC. $10,664.67 04/17/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192174937
Principal investigator 1 AstraZeneca UK Limited $6,672.00 04/16/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome No dispute reported 06/30/2026 1185552259
Principal investigator 1 Incyte Corporation $1,607.40 04/14/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560687
Principal investigator 1 United Therapeutics Corporation $864.00 04/09/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386849
Principal investigator 1 United Therapeutics Corporation $864.00 04/09/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386867
Principal investigator 1 AstraZeneca UK Limited $665.58 04/08/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185552239
Principal investigator 1 Incyte Corporation $11.45 04/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560726
Principal investigator 1 Incyte Corporation $57.85 04/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560750
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 04/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623412
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 04/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623414
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 04/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623418
Principal investigator 1 GENZYME CORPORATION $3,364.00 03/24/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138943
Principal investigator 1 GlaxoSmithKline, LLC. $12,825.00 03/21/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192178748
Principal investigator 1 GlaxoSmithKline, LLC. $2,595.00 03/21/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192178766
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,600.80 03/17/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791759
Principal investigator 1 Incyte Corporation $2,469.00 03/14/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560582
Principal investigator 1 Incyte Corporation $1,975.20 03/14/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560681
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,550.00 03/12/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) No dispute reported 06/30/2026 1185552219
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,952.50 03/10/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791757
Principal investigator 1 Genentech, Inc. $892.00 03/07/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211628986
Principal investigator 1 GlaxoSmithKline, LLC. $3,297.74 03/06/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192177685
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 03/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623396
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 03/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623398
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 03/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623400
Principal investigator 1 United Therapeutics Corporation $205.20 02/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386841
Principal investigator 1 United Therapeutics Corporation $1,728.00 02/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386857
Principal investigator 1 United Therapeutics Corporation $1,728.00 02/26/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386877
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 02/25/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623406
Principal investigator 1 GENZYME CORPORATION $990.00 02/24/2025 Non-covered Recipient Entity
Newportnativemd Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226138947
Principal investigator 1 Insmed, Inc. $1,121.45 02/21/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645978
Principal investigator 1 Insmed, Inc. $230.85 02/21/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645980
Principal investigator 1 Insmed, Inc. $157.95 02/21/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645982
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 02/20/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192173964
Principal investigator 1 Incyte Corporation $1,072.80 02/19/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560617
Principal investigator 1 Incyte Corporation $1,805.00 02/19/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560624
Principal investigator 1 Incyte Corporation $1,856.00 02/19/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560632
Principal investigator 1 Incyte Corporation $1,856.00 02/19/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560637
Principal investigator 1 United Therapeutics Corporation $2,851.20 02/12/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386843
Principal investigator 1 SANOFI US SERVICES INC. $17,400.00 02/10/2025 Non-covered Recipient Entity
Newportnativemd Inc
A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps No dispute reported 06/30/2026 1226138955
Principal investigator 1 GlaxoSmithKline, LLC. $751.00 02/07/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192174957
Principal investigator 1 GlaxoSmithKline, LLC. $751.00 02/07/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177713
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 02/06/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192174928
Principal investigator 1 Insmed, Inc. $0.88 02/05/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645958
Principal investigator 1 Insmed, Inc. $16,073.96 02/05/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645962
Principal investigator 1 Insmed, Inc. $1.38 02/05/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645966
Principal investigator 1 Insmed, Inc. $0.92 02/05/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645972
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 02/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623390
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 02/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623392
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 02/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623394
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,070.57 01/31/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185552229
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,846.86 01/29/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1185552243
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,980.16 01/29/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185552247
Principal investigator 1 United Therapeutics Corporation $2,851.20 01/29/2025 Non-covered Recipient Entity
NewportNativeMD Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242386845
Principal investigator 1 United Therapeutics Corporation $10,652.85 01/29/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386899
Principal investigator 1 Amgen Inc. $27,793.59 01/27/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246645290
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 01/27/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623402
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 01/27/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623404
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,606.30 01/27/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791755
Principal investigator 1 Insmed, Inc. $15,000.00 01/24/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645974
Principal investigator 1 Insmed, Inc. $1,500.00 01/24/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645976
Principal investigator 1 AstraZeneca Pharmaceuticals LP $224,234.45 01/17/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185552217
Principal investigator 1 Incyte Corporation $1,805.00 01/17/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560607
Principal investigator 1 Incyte Corporation $1,444.00 01/17/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560613
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,081.34 01/15/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185552221
Principal investigator 1 GlaxoSmithKline, LLC. $5,149.80 01/13/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192178771
Principal investigator 1 GlaxoSmithKline, LLC. $4,136.47 01/09/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192178752
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,959.68 01/08/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase III Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma No dispute reported 06/30/2026 1185552235
Principal investigator 1 Insmed, Inc. $0.44 01/08/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645960
Principal investigator 1 Insmed, Inc. $6,888.84 01/08/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645964
Principal investigator 1 Insmed, Inc. $0.92 01/08/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645968
Principal investigator 1 Insmed, Inc. $0.46 01/08/2025 Non-covered Recipient Entity
NewportNativeMD, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645970
Principal investigator 1 United Therapeutics Corporation $2,898.00 01/08/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386891
Principal investigator 1 United Therapeutics Corporation $11,000.00 01/08/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242386901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,279.90 01/06/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220791753
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,887.55 01/03/2025 Non-covered Recipient Entity
NEWPORTNATIVEMD, INC.
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552253
Principal investigator 1 Incyte Corporation $46.08 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560588
Principal investigator 1 Incyte Corporation $10.78 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560601
Principal investigator 1 Incyte Corporation $57.81 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560643
Principal investigator 1 Incyte Corporation $99.12 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560651
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560658
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560664
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560671
Principal investigator 1 Incyte Corporation $30.52 01/02/2025 Non-covered Recipient Entity
NEWPORT NATIVE MD
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240560676
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 01/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623408
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 01/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623410
Principal investigator 1 Boehringer Ingelheim International GmbH $194.99 01/01/2025 Non-covered Recipient Entity
NewportNativeMD Inc
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220623416